statistiche ricercatore

Continente	#
AS - Asia	428
NA - Nord America	392
EU - Europa	295
SA - Sud America	64
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.195

Nazione	#
US - Stati Uniti d'America	378
SG - Singapore	161
CN - Cina	149
IT - Italia	68
GB - Regno Unito	58
BR - Brasile	55
HK - Hong Kong	51
DE - Germania	39
SE - Svezia	27
NL - Olanda	24
RU - Federazione Russa	24
IN - India	18
VN - Vietnam	13
FR - Francia	10
DK - Danimarca	8
FI - Finlandia	8
IE - Irlanda	8
KR - Corea	8
CA - Canada	7
CI - Costa d'Avorio	6
EG - Egitto	5
ES - Italia	4
JP - Giappone	4
MX - Messico	4
UA - Ucraina	4
AT - Austria	3
ID - Indonesia	3
PL - Polonia	3
TR - Turchia	3
AR - Argentina	2
AZ - Azerbaigian	2
BD - Bangladesh	2
CH - Svizzera	2
CO - Colombia	2
CY - Cipro	2
IQ - Iraq	2
NP - Nepal	2
SA - Arabia Saudita	2
SN - Senegal	2
UZ - Uzbekistan	2
AO - Angola	1
BE - Belgio	1
EC - Ecuador	1
GT - Guatemala	1
HN - Honduras	1
JM - Giamaica	1
KG - Kirghizistan	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LU - Lussemburgo	1
LV - Lettonia	1
PE - Perù	1
PK - Pakistan	1
PT - Portogallo	1
PY - Paraguay	1
TN - Tunisia	1
TW - Taiwan	1
UY - Uruguay	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.195

Nome	#
Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards	169
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown	155
Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis	149
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	121
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors	117
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)	100
MAFLD and NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality?	98
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	98
Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIII	80
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease	78
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients	72
Totale	1.237

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	16	0	0	0	0	0	0	1	3	7	1	3	1
2021/2022	63	2	2	7	4	5	2	2	4	6	6	4	19
2022/2023	110	12	14	9	13	11	17	1	7	18	1	7	0
2023/2024	83	0	8	3	8	33	4	2	1	5	1	6	12
2024/2025	389	15	25	21	25	19	17	25	30	29	40	63	80
2025/2026	462	91	72	111	72	66	40	10	0	0	0	0	0
Totale													1.237

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca